Recent standard of care Articles
There is good news in the advancement of chemo-free approaches to managing chronic lymphocytic leukemia, and I am thrilled to share it with you. Results of the phase III ECOG trial found that the combination of ibrutinib (Imbruvica) plus rituximab (Rituxan) came out superior to the chemotherapy and immunotherapy (chemoimmunotherapy) grouping of fludarabine, cyclophosphamide, and rituximab, known as FCR.
Chemotherapy is imperfect—most drugs are. But I absolutely support its use for cancer treatment when called for as the approved standard of care, when there is solid potential to ensure a durable remission.